Imperagen uses quantum simulation and AI to engineer enzymes faster and cheaper than traditional methods.
$6.3MSeed
A $6.3M seed for computational biotech signals that VCs are betting on simulation-first drug discovery—the bet is that quantum + AI can compress years of wet-lab iteration into months. If you're building in adjacent biotech infrastructure (ADME prediction, protein folding, synthetic biology tooling), this validates that computational de-risking is fundable before you have clinical data; the capital is flowing to founders who can show computational shortcuts to expensive experiments.